Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOST52
|
|||
| Drug Name |
MK-1654
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 2/3 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Respiratory syncytial virus protein F (RSV F) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04767373) Efficacy and Safety of MK-1654 in Infants (MK-1654-004). U.S. National Institutes of Health. | |||
| REF 2 | A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.